DJIA 17,098.45 18.88 0.11%
NASDAQ 4,580.27 0.00 0.00%
S&P 500 2,003.37 6.63 0.33%
market minute promo


4.29 0.15 (3.62%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

VVUS $4.29 3.62%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $4.13
Previous Close $4.14
Daily Range $4.13 - $4.30
52-Week Range $4.06 - $12.90
Market Cap $443.8M
P/E Ratio -4.13
Dividend (Yield) $0.00 (0.0%)
Volume 1,333,383
Average Daily Volume 1,359,827
Current FY EPS -$1.06





VIVUS, Inc. (VVUS) Description

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products. Website:

News & Commentary Rss Feed

3 Simple Ways to Invest Like George Soros

George Soros is one of the most successful investors of all time. Here are three easy ways to follow in his footsteps.

Belviq Sales Crack Critical Level

VIVUS Acquires Certain Topamax Related Patents from J&J - Analyst Blog

Vivus Acquires Patent Rights To Qsymia Ingredient

Advertising And The Belviq Re-Launch

Biotech Investing: 3 Ways You're Doing It Wrong

Biotech investing might appear easy considering some of the big gains we've witnessed in recent years, but these three common mistakes make it very difficult for the average biotech investor to make money.

Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind

Arena And VIVUS: A Case Study In Small-Cap Pharma

Belviq Sales Flatten Out But Edge Above Qsymia

FDA Data: Good News For One Anti-Obesity Company, Not So Good For Another

See More VVUS News...

VVUS's Top Competitors

VVUS $4.29 (3.62%)
Current stock: VVUS
JNJ $103.73 (0.76%)
Current stock: JNJ
NVS $89.84 (0.12%)
Current stock: NVS
RHHBY $36.51 (-0.14%)
Current stock: RHHBY